New Delhi, Dec. 10 -- French pharmaceutical group Servier is sharpening its India strategy with a string of new oncology launches focused on rare cancers, plans for local manufacturing of active ingredients, and a move to bring global clinical trials to the country for the first time. The shift marks a significant elevation of India in Servier's global priorities, aligning it almost in step with launches in the western markets.

"Our forecast in terms of development is that we'll be able to steadily grow our historical cardiovascular-metabolism-diabetes portfolio, and we'll be able to scale up drastically in oncology, meaning the share of India by itself within the group is going to increase," Aurelien Breton, managing director of Servier...